Plus Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $411 | $1,028 | $1,367 | $1,397 |
Gross Profit | -919 | 919 | 1,275 | 1,311 |
EBITDA | -9,057 | -6,820 | -2,327 | -4,337 |
EBIT | -8,948 | -6,929 | -2,384 | -4,423 |
Net Income | -9,006 | -6,946 | -5,713 | -4,423 |
Net Change In Cash | 411 | 1,028 | 1,367 | 1,397 |
Free Cash Flow | -7,631 | -7,056 | -6,287 | -2,575 |
Cash | 2,366 | 3,022 | 8,758 | 13,289 |
Basic Shares | 6,773 | 6,646 | 3,112 | 1,074,289 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $5,213 | $5,824 | $4,913 | $224 |
Gross Profit | 4,768 | 4,972 | -4,777 | -488 |
EBITDA | -18,332 | -8,402 | -12,293 | -18,852 |
EBIT | -18,777 | -9,254 | -12,921 | -19,564 |
Net Income | -22,386 | -12,978 | -13,316 | -20,275 |
Net Change In Cash | 5,213 | 5,824 | 4,913 | 224 |
Free Cash Flow | -20,842 | -10,700 | -13,011 | -13,731 |
Cash | 8,758 | 76 | 8,554 | 18,120 |
Basic Shares | 3,112 | 308 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$1.05 |
2025-12-31 | -$0.04 |
2025-09-30 | -$1 |
2025-06-30 | -$0.16 |